Spike protein antibody and pathogen and serology reagents: two different questions

Choosing and interpreting

1. Separate antigen detection from serology. Detecting a pathogen protein indicates the organism is present. Detecting host antibodies indicates exposure, possibly long past, and possibly from vaccination. State which the assay does.
2. Ask about variant coverage. For organisms that change quickly, a reagent raised against one variant may bind others weakly or not at all. Coverage has to be stated and, for anything important, tested against the variants in circulation.
3. Handle samples at the right containment. Clinical and environmental samples carry infectious risk that depends on the agent. Containment level, waste route and vaccination requirements are decided before the first sample arrives.
4. Use immunogen and carrier reagents as controls. Reagents against common carriers and model antigens are experimental tools: they calibrate an assay, check a conjugation and provide a negative. They are not diagnostics and should not be presented as such.
5. Consider anti carrier responses in formulated products. Responses against polymer carriers used in formulation are measurable and clinically relevant, and reagents against them belong in the bioanalytical package for those products.

Exposure, infection and protection are three claims

A serology result establishes exposure. It does not establish current infection, and it does not establish protection, because binding and neutralisation are different properties measured by different assays.

Say which claim the data supports. The distinction is routinely blurred in reporting and it is the source of most misinterpretation in this area.

Research use only means what it says

Reagents in this group are frequently sold for research use and used to answer questions that look clinical. The labelling clause exists precisely for that boundary, and it constrains what may be claimed rather than what may be measured.

Where a result will inform care, the assay and the reagents have to be appropriate to that use. Where it will not, say so plainly in the write up.

rbd protein, and why the domain is used alone

The receptor binding domain is the part of a viral spike that contacts the host receptor, and it is expressed on its own because it is small, folds without the rest of the trimer and carries most of the neutralising epitopes. That makes it the practical antigen for serology, for competition assays against receptor binding, and for selecting binders. What it loses is the quaternary epitopes that only exist on the assembled spike, so a negative result against the domain is not a negative against the whole protein, and a vaccine response is read against both.

hsv1 antibodies and the two things measured

hsv1 antibodies means either reagents against viral proteins, used to detect infected cells and to type an isolate, or a patient's own antibodies measured as evidence of infection, and type specific serology relies on one glycoprotein because the two types cross react extensively. For a research reagent the viral protein and its expression phase are what the datasheet has to state.

A strongyloides igg antibody test and what it cannot say

A strongyloides igg antibody result shows exposure rather than current infection, and it cross reacts with other helminths, which is why a positive is interpreted with the exposure history and, where it matters, confirmed. Sensitivity falls in the immunosuppressed, which is exactly the population screened before therapy, and that limitation belongs beside the result.

An lps elisa kit and the endotoxin question behind it

An lps elisa kit measures bacterial lipopolysaccharide immunologically, which is a different measurement from the pyrogen assays used for release testing, and the two do not agree because the immunoassay detects structure while the clotting based assay detects biological activity. For a regulated release the compendial method is what applies; the kit is a research tool.

food allergen test kits and the methods behind them

food allergen test kits are immunoassays against a named protein, either a rapid lateral flow for a factory line or a plate assay for a laboratory number, and processing changes what they can see because heating alters the epitopes. A negative therefore applies to the matrix the kit was validated on, which is why the validated matrix list matters more than the detection limit.

An hbsag antibody and the two things the phrase means

An hbsag antibody may be the reagent that detects the hepatitis B surface antigen or the patient response measured after vaccination, and the two have nothing to do with each other in a catalogue. For the reagent, the subtype it recognises decides whether an assay reads every circulating variant, which is what an immunoassay has to declare.

Common questions

Does a positive serology result mean current infection?

No. It indicates exposure at some point, which may include vaccination. Current infection is established by detecting the organism or its components, or by a rise in titre between paired samples.

Will an RBD antibody raised against one variant detect others?

Not reliably. Coverage depends on where the epitope sits and how conserved it is, and it has to be stated by the supplier and ideally tested locally against circulating variants.

Why do assays include antibodies against carrier proteins?

As controls and tools: to check a conjugation worked, to provide a negative, or to measure a response against a carrier used in a formulation. They are not diagnostic reagents.

Browse by service class

• Compare Gene synthesis on advertised prices